Kane Biotech (CVE:KNE) Shares Up 28.6% – Time to Buy?

Kane Biotech Inc. (CVE:KNE)’s share price shot up 28.6% during mid-day trading on Friday . The company traded as high as C$0.05 and last traded at C$0.05. 1,505,028 shares changed hands during mid-day trading, an increase of 380% from the average session volume of 313,629 shares. The stock had previously closed at C$0.04.

Kane Biotech Price Performance

The company has a market cap of C$7.53 million, a PE ratio of -0.56 and a beta of 0.60. The company has a debt-to-equity ratio of -331.42, a current ratio of 0.80 and a quick ratio of 0.39. The stock’s 50-day moving average is C$0.04 and its 200 day moving average is C$0.04.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.